Reduced tyrosine hydroxylase and GTP cyclohydrolase mRNA expression, tyrosine hydroxylase activity, and associated neurochemical alterations in Nurr1-null heterozygous mice

Brain Research Bulletin

Volumn 70, Issue 2, 2006, Pages 186-195

  Eells, Jeffrey B ^a   Misler, Jaime A ^a   Nikodem, Vera M ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Dopamine synthesis; GTP cyclohydrolase; NR4A2; Nurr1; Tyrosine hydroxylase

Indexed keywords

AROMATIC LEVO AMINO ACID DECARBOXYLASE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; GAMMA BUTYROLACTONE; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; MESSENGER RNA; NUCLEAR RECEPTOR RELATED FACTOR 1; TYROSINE 3 MONOOXYGENASE; VESICULAR MONOAMINE TRANSPORTER;

ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; ENZYME ACTIVITY; GENE EXPRESSION; LIMBIC CORTEX; MESENCEPHALON; MOUSE; NERVE CELL; NEUROCHEMISTRY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TEGMENTUM; WILD TYPE;

ANIMALS; ANIMALS, NEWBORN; DNA-BINDING PROTEINS; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GTP CYCLOHYDROLASE; MICE; MICE, KNOCKOUT; RNA, MESSENGER; TRANSCRIPTION FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 33745009011     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2006.05.004     Document Type: Article

References (57)

1. Backman C., You Z.B., Perlmann T., and Hoffer B.J. Elevated locomotor activity without altered striatal dopamine contents in Nurr1 heterozygous mice after acute exposure to methamphetamine. Behav. Brain Res. 143 (2003) 95-100
2. Bolam J.P., and Smith Y. The GABA substance P input to dopaminergic neurones in the substantia nigra of the rat. Brain Res. 529 (1990) 57-78
3. Buervenich S., Carmine A., Arvidsson M., Xiang F., Zhang Z., Sydow O., Jonsson E.G., Sedvall G.C., Leonard S., Ross R.G., Freedman R., Chowdari K.V., Nimgaonkar V.L., Perlmann T., Anvret M., and Olson L. NURR1 mutations in cases of schizophrenia and manic-depressive disorder. Am. J. Med. Genet. 96 (2000) 808-813
4. Bunney B.S., Chiodo L.A., and Grace A.A. Midbrain dopamine system electrophysiological functioning: a review and new hypothesis. Synapse 9 (1991) 79-94
5. Carlsson A., Waters N., Holm-Waters S., Tedroff J., Nilsson M., and Carlsson M.L. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu. Rev. Pharmacol. Toxicol. 41 (2001) 237-260
6. Castillo S.O., Baffi J.S., Palkovits M., Goldstein D.S., Kopin I.J., Witta J., Magnuson M.A., and Nikodem V.M. Dopamine biosynthesis is selectively abolished in substantia nigra/ventral tegmental area but not in hypothalamic neurons in mice with targeted disruption of the Nurr1 gene. Mol. Cell Neurosci. 11 (1998) 36-46
7. Chen Y.H., Tsai M.T., Shaw C.K., and Chen C.H. Mutation analysis of the human NR4A2 gene, an essential gene for midbrain dopaminergic neurogenesis, in schizophrenic patients. Am. J. Med. Genet. 105 (2001) 753-757
8. Chung S., Sonntag K.C., Andersson T., Bjorklund L.M., Park J.J., Kim D.W., Kang U.J., Isacson O., and Kim K.S. Genetic engineering of mouse embryonic stem cells by Nurr1 enhances differentiation and maturation into dopaminergic neurons. Eur. J. Neurosci. 16 (2002) 1829-1838
9. Eells J.B. The control of dopamine neuron development, function and survival: insights from transgenic mice and the relevance to human disease. Curr. Med. Chem. 10 (2003) 857-870
10. Eells J.B., Lipska B.K., Yeung S.K., Misler J.A., and Nikodem V.M. Nurr1-null heterozygous mice have reduced mesolimbic and mesocortical dopamine levels and increased stress-induced locomotor activity. Behav. Brain Res. 136 (2002) 267
11. J.B. Eells, J.A. Misler, V.M. Nikodem, Early postnatal isolation reduces dopamine levels, elevates dopamine turnover and specifically disrupts prepulse inhibition in Nurr1-null heterozygous mice, Neuroscience (2006), in press.
12. Eells J.B., Rives J.E., Yeung S.K., and Nikodem V.M. In vitro regulated expression of tyrosine hydroxylase in ventral midbrain neurons from Nurr1-null mouse pups. J. Neurosci. Res. 64 (2001) 322-330
13. Eells J.B., Witta J., Otridge J.B., Zuffova E., and Nikodem V.M. Structure and function of the Nur77 subfamily, a unique class of hormone nuclear receptors. Cur. Genomics 1 (2000) 135-152
14. Eells J.B., Yeung S.K., and Nikodem V.M. Dopamine neurons heterozygous for the Nurr1-Null allele have reduced survival in vitro. Neurosci. Res. Comm. 30 (2002) 173-183
15. Hattori N., Kobayashi H., Sasaki-Hatano Y., Sato K., and Mizuno Y. Familial Parkinson's disease: a hint to elucidate the mechanisms of nigral degeneration. J. Neurol. 250 (2003) 2-10
16. Haycock J.W., and Haycock D.A. Tyrosine hydroxylase in rat brain dopaminergic nerve terminals. Multiple-site phosphorylation in vivo and in synaptosomes. J. Biol. Chem. 266 (1991) 5650-5657
17. Holmes C., Eisenhofer G., and Goldstein D.S. Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection. J. Chromatogr. B Biomed. Appl. 653 (1994) 131-138
18. Hwang O., Baker H., Gross S., and Joh T.H. Localization of GTP cyclohydrolase in monoaminergic but not nitric oxide-producing cells. Synapse 28 (1998) 140-153
19. Hyland K., Gunasekera R.S., Engle T., and Arnold L.A. Tetrahydrobiopterin and biogenic amine metabolism in the hph-1 mouse. J. Neurochem. 67 (1996) 752-759
20. Iwawaki T., Kohno K., and Kobayashi K. Identification of a potential Nurr1 response element that activates the tyrosine hydroxylase gene promoter in cultured cells. Biochem. Biophys. Res. Commun. 274 (2000) 590-595
21. Jankovic J., Chen S., and Le W.D. The role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease. Prog. Neurobiol. 77 (2005) 128-138
22. Jiang C., Wan X., He Y., Pan T., Jankovic J., and Le W. Age-dependent dopaminergic dysfunction in Nurr1 knockout mice. Exp. Neurol. 191 (2005) 154-162
23. Jones D.M., Arters J., and Berger-Sweeney J. Carbon dioxide-induced anesthesia has no effect on brain biogenic amine concentrations in mice. Lab. Anim. Sci. 49 (1999) 316-318
24. Jones S.R., Gainetdinov R.R., Jaber M., Giros B., Wightman R.M., and Caron M.G. Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 4029-4034
25. Kim K.S., Kim C.H., Hwang D.Y., Seo H., Chung S., Hong S.J., Lim J.K., Anderson T., and Isacson O. Orphan nuclear receptor Nurr1 directly transactivates the promoter activity of the tyrosine hydroxylase gene in a cell-specific manner. J. Neurochem. 85 (2003) 622-634
26. Kim T.E., Lee H.S., Lee Y.B., Hong S.H., Lee Y.S., Ichinose H., Kim S.U., and Lee M.A. Sonic hedgehog and FGF8 collaborate to induce dopaminergic phenotypes in the Nurr1-overexpressing neural stem cell. Biochem. Biophys. Res. Commun. 305 (2003) 1040-1048
27. Kobayashi K., Morita S., Sawada H., Mizuguchi T., Yamada K., Nagatsu I., Hata T., Watanabe Y., Fujita K., and Nagatsu T. Targeted disruption of the tyrosine hydroxylase locus results in severe catecholamine depletion and perinatal lethality in mice. J. Biol. Chem. 270 (1995) 27235-27243
28. Kumer S.C., and Vrana K.E. Intricate regulation of tyrosine hydroxylase activity and gene expression. J. Neurochem. 67 (1996) 443-462
29. Le W., Conneely O.M., He Y., Jankovic J., and Appel S.H. Reduced Nurr1 expression increases the vulnerability of mesencephalic dopamine neurons to MPTP-induced injury. J. Neurochem. 73 (1999) 2218-2221
30. Le W.D., Xu P., Jankovic J., Jiang H., Appel S.H., Smith R.G., and Vassilatis D.K. Mutations in NR4A2 associated with familial Parkinson disease. Nat. Genet. 33 (2003) 85-89
31. Leenders K.L. Disease process and drug treatments in Parkinson's disease. Eur. Neuropsychopharmacol. 12 (2002) 575-580
32. Lew J.Y., Garcia-Espana A., Lee K.Y., Carr K.D., Goldstein M., Haycock J.W., and Meller E. Increased site-specific phosphorylation of tyrosine hydroxylase accompanies stimulation of enzymatic activity induced by cessation of dopamine neuronal activity. Mol. Pharmacol. 55 (1998) 202-209
33. McDonald J.D., Cotton R.G., Jennings I., Ledley F.D., Woo S.L., and Bode V.C. Biochemical defect of the hph-1 mouse mutant is a deficiency in GTP-cyclohydrolase activity. J. Neurochem. 50 (1988) 655-657
34. Paulsen R.F., Granas K., Johnsen H., Rolseth V., and Sterri S. Three related brain nuclear receptors, NGFI-B, Nurr1, and NOR-1, as transcriptional activators. J. Mol. Neurosci. 6 (1995) 249-255
35. Philips A., Maira M., Mullick A., Chamberland M., Lesage S., Hugo P., and Drouin J. Antagonism between Nur77 and glucocorticoid receptor for control of transcription. Mol. Cell Biol. 17 (1997) 5952-5959
36. Ramsey A.J., and Fitzpatrick P.F. Effects of phosphorylation on binding of catecholamines to tyrosine hydroxylase: specificity and thermodynamics. Biochemistry 39 (2000) 773-778
37. Sacchetti P., Mitchell T.R., Granneman J.G., and Bannon M.J. Nurr1 enhances transcription of the human dopamine transporter gene through a novel mechanism. J. Neurochem. 76 (2001) 1565-1572
38. Sakurada K., Ohshima-Sakurada M., Palmer T.D., and Gage F.H. Nurr1, an orphan nuclear receptor, is a transcriptional activator of endogenous tyrosine hydroxylase in neural progenitor cells derived from the adult brain. Development 126 (1999) 4017-4026
39. Salvatore M.F., Garcia-Espana A., Goldstein M., Deutch A.Y., and Haycock J.W. Stoichiometry of tyrosine hydroxylase phosphorylation in the nigrostriatal and mesolimbic systems in vivo: effects of acute haloperidol and related compounds. J. Neurochem. 75 (2000) 225-232
40. Saucedo-Cardenas O., Quintana-Hau J.D., Le W.D., Smidt M.P., Cox J.J., De Mayo F., Burbach J.P., and Conneely O.M. Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 4013-4018
41. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1 (1987) 133-152
42. Shimoji M., Hirayama K., Hyland K., and Kapatos G. GTP cyclohydrolase I gene expression in the brains of male and female hph-1 mice. J. Neurochem. 72 (1999) 757-764
43. Smith K.M., Bauer L., Fischer M., Barkley R., and Navia B.A. Identification and characterization of human NR4A2 polymorphisms in attention deficit hyperactivity disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 133 (2005) 57-63
44. Smith Y., Charara A., and Parent A. Synaptic innervation of midbrain dopaminergic neurons by glutamate-enriched terminals in the squirrel monkey. J. Comp. Neurol. 364 (1996) 231-253
45. Smits S.M., Ponnio T., Conneely O.M., Burbach J.P., and Smidt M.P. Involvement of Nurr1 in specifying the neurotransmitter identity of ventral midbrain dopaminergic neurons. Eur. J. Neurosci. 18 (2003) 1731-1738
46. Solanto M.V. Dopamine dysfunction in AD/HD: integrating clinical and basic neuroscience research. Behav. Brain Res. 130 (2002) 65-71
47. Solberg Y., Silverman W.F., and Pollack Y. Prenatal ontogeny of tyrosine hydroxylase gene expression in the rat ventral mesencephalon. Brain Res. Dev. Brain Res. 73 (1993) 91-97
48. Sumi-Ichinose C., Urano F., Kuroda R., Ohye T., Kojima M., Tazawa M., Shiraishi H., Hagino Y., Nagatsu T., Nomura T., and Ichinose H. Catecholamines and serotonin are differently regulated by tetrahydrobiopterin. A study from 6-pyruvoyltetrahydropterin synthase knockout mice. J. Biol. Chem. 276 (2001) 41150-41160 Epub 42001 Aug 41121
49. Sumi-Ichinose C., Urano F., Shimomura A., Sato T., Ikemoto K., Shiraishi H., Senda T., Ichinose H., and Nomura T. Genetically rescued tetrahydrobiopterin-depleted mice survive with hyperphenylalaninemia and region-specific monoaminergic abnormalities. J. Neurochem. 95 (2005) 703-714 Epub 2005 Aug 2031
50. Svensson T.H. Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs. Brain Res. Brain Res. Rev. 31 (2000) 320-329
51. Tseng K.Y., Roubert C., Do L., Rubinstein M., Kelly M.A., Grandy D.K., Low M.J., Gershanik O.S., Murer M.G., Giros B., and Raisman-Vozari R. Selective increase of Nurr1 mRNA expression in mesencephalic dopaminergic neurons of D2 dopamine receptor-deficient mice. Brain Res. Mol. Brain Res. 80 (2000) 1-6
52. Wallen A., Zetterstrom R.H., Solomin L., Arvidsson M., Olson L., and Perlmann T. Fate of mesencephalic AHD2-expressing dopamine progenitor cells in NURR1 mutant mice. Exp. Cell Res. 253 (1999) 737-746
53. Xu P.Y., Liang R., Jankovic J., Hunter C., Zeng Y.X., Ashizawa T., Lai D., and Le W.D. Association of homozygous 7048G7049 variant in the intron six of Nurr1 gene with Parkinson's disease. Neurology 58 (2002) 881-884
54. Zetterstrom R.H., Solomin L., Jansson L., Hoffer B.J., Olson L., and Perlmann T. Dopamine neuron agenesis in Nurr1-deficient mice. Science 276 (1997) 248-250
55. Zetterstrom R.H., Solomin L., Mitsiadis T., Olson L., and Perlmann T. Retinoid X receptor heterodimerization and developmental expression distinguish the orphan nuclear receptors NGFI-B, Nurr1, and Nor1. Mol. Endocrinol. 10 (1996) 1656-1666
56. Zetterstrom R.H., Williams R., Perlmann T., and Olson L. Cellular expression of the immediate early transcription factors Nurr1 and NGFI-B suggests a gene regulatory role in several brain regions including the nigrostriatal dopamine system. Brain Res. Mol. Brain Res. 41 (1996) 111-120
57. Zigmond R.E., Schwarzschild M.A., and Rittenhouse A.R. Acute regulation of tyrosine hydroxylase by nerve activity and by neurotransmitters via phosphorylation. Annu. Rev. Neurosci. 12 (1989) 415-461